UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses the evolution of surgery in the treatment of patients with ovarian cancer.

Maggie DiNome, MD, discusses the evolution of surgical approaches in patients with early-stage breast cancer.

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

Susan A. McCloskey, MD, discusses the use of postoperative radiation in patients with breast cancer.

Sara Hurvitz, MD, shares insight on the 3 CDK4/6 inhibitors approved in HR-positive breast cancer, and looks toward the future of these agents, which will likely include combination strategies.

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical use of biosimilars in oncology.

Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.

Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Denise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.

Sanaz Memarzadeh, MD, PhD, associate professor of Obstetrics and Gynecology, and the director of the Gynecologic Oncology Discovery Lab at UCLA, discusses her preclinical research on resistant tumor cells in ovarian cancer.

Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.

dward Garon, MD, assistant professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles, discusses incorporating immunotherapies into the treatment of patients with lung cancer.

International study co-led by Dr. Antoni Ribas finds vemurafenib and cobimetinib extend lives and decrease risk of side effects in men and women with melanoma.

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.

Dennis J. Slamon, MD, PhD, discusses the impact of the ADAPT and BOLERO trials and how the increased focus on neoadjuvant therapy with trastuzumab and T-DM1 could transform the treatment of HER2-positive breast cancer.

Sanaz Memarzadeh, MD, PhD, discusses a combination regimen of birinapant and carboplatin in patients with high-grade serous ovarian cancers and high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA-125–negative cells.

Dennis Slamon, MD, PhD, discusses the inhibition of CDK 4/6 and PD-1, which represent two of the most exciting developments in the field of metastatic breast cancer.

OncLive's editorial and marketing groups will spread the news about the center's community outreach and research programs.

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced NSCLC across all histologies whose disease has progressed on or after platinum-containing chemotherapy, as well as a targeted agent in EGFR- or ALK-positive patients.

Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

For further insight on the significance of palbociclib's approval, OncLive sat down with the lead investigator of PALOMA-1, Richard Finn, MD, from the Jonsson Comprehensive Cancer Center at UCLA.

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.

To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.